EUVIMEDEUVIMED entdecken
Crossref

L26/P-408 Rescue Fertility Preservation After Gonadotoxic Treatments for Malignant and Benign Diseases: A Single Tertiary Centre Experience

G. Altinier, A. Borras, Y. Barral, I. Agustí, M. Mendez, G. Casals, D. Manau

Human Reproduction · 01.07.2026 · 41 (Supplement_1)

DOI: 10.1093/humrep/deag083.742 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von G. Altinier und 6 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Study question Is fertility preservation effective and clinically justified in women previously treated with gonadotoxic therapies using controlled ovarian stimulation? Summary answer Fertility preservation yielded satisfactory mature oocytes regardless of prior gonadotoxic treatment, emphasizing the need for individualized criteria based on reproductive goals, ovarian reserve,and recurrence risk. What is known already Indications for fertility preservation (FP) have expanded in recent years, particularly among women undergoing gonadotoxic treatments for cancer and certain benign diseases. Many patients are unable to undergo FP before treatment initiation, raising concerns about premature ovarian insufficiency. However, the usefulness of FP in women with reduced ovarian reserve or after chemotherapy remains controversial. Some studies have suggested the feasibility of FP after gonadotoxic injury, but these reports include few cases, and clear criteria for patient selection into fertility preservation programs have not yet been established. Study design, size, duration This retrospective observational study included 55 delayed or rescue fertility preservation cycles performed in 44 patients at a single tertiary referral hospital serving a population of 1.5 million. Cycles were conducted after gonadotoxic treatment for cancer or benign diseases and represent all cases recruited in the fertility preservation program up to December 2024 at the same tertiary fertility center. Participants/materials, setting, methods Women undergoing fertility preservation after gonadotoxic treatment for oncologic or benign conditions were included at a single tertiary fertility center. Data collected comprised age, diagnosis, prior chemotherapy, anti-Müllerian hormone (AMH) levels, and total and mature (MII) oocytes retrieved. Rescue fertility preservation was individualized for each patient based on reproductive desire and ovarian reserve markers. Main results and the role of chance A total of 55 fertility preservation cycles were performed in 44 patients, of which 44 (80%) were related to oncologic conditions and 11 (20%) to benign diseases. Hematologic malignancies accounted for 42.6% of cases, solid tumors for 37%, and medical indications for 20.4%. Overall, 35 patients (69%) had received prior chemotherapy. The mean age at fertility preservation was 24.7 +/- 6.1 years, with similar ages between oncologic (25 +/- 6.2 years) and non-oncologic patients (23.5 +/- 5.8 years), p-value 0.54. Median AMH was 0.99 ng/ml in the oncologic group and 0.9 ng/ml in the non-oncologic group (no significant differences). These values indicate comparable ovarian reserve between patients with oncologic and non-oncologic conditions undergoing fertility preservation. The mean number of retrieved oocytes and mature (MII) oocytes varied slightly by diagnosis: patients with hematologic malignancies yielded a mean of 5 oocytes and 4 MII, those with solid tumors 7 oocytes and 6 MII, and those with medical indications 8 oocytes and 7 MII. Despite prior gonadotoxic exposure, oocyte yield and maturity were satisfactory across all groups, with no significant differences between oncologic and non-oncologic patients, or among diagnostic subgroups within the oncologic cohort. Limitations, reasons for caution Limitations include the retrospective design, small sample size and lack of a control group, which may limit generalizability. Wider implications of the findings Rescue fertility preservation after gonadotoxic treatment is feasible and effective, even when FP cannot be performed beforehand. Clearer definitions are needed, with general criteria adapted individually based on reproductive goals, ovarian reserve, and, in cases like lymphoma, the risk of recurrence and potential need for further gonadotoxic therapies. Trial registration number No

Zitieren

APA

Altinier, G., Borras, A., Barral, Y., Agustí, I., Mendez, M., Casals, G., & Manau, D. (2026). L26/P-408 Rescue Fertility Preservation After Gonadotoxic Treatments for Malignant and Benign Diseases: A Single Tertiary Centre Experience. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.742

Vancouver

Altinier G, Borras A, Barral Y, Agustí I, Mendez M, Casals G, et al. L26/P-408 Rescue Fertility Preservation After Gonadotoxic Treatments for Malignant and Benign Diseases: A Single Tertiary Centre Experience. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.742

BibTeX
@article{Altinier2026,
  author = {Altinier, G. and Borras, A. and Barral, Y. and Agustí, I. and Mendez, M. and Casals, G. and Manau, D.},
  title = {L26/P-408 Rescue Fertility Preservation After Gonadotoxic Treatments for Malignant and Benign Diseases: A Single Tertiary Centre Experience},
  journal = {Human Reproduction},
  year = {2026},
  volume = {41},
  number = {Supplement_1},
  doi = {10.1093/humrep/deag083.742}
}
Kostenlos starten →